Skip to main content

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content
Hamburger button
Close button

Patient Support Program

Receive updates and information from the TYVASO Support Program

Are you considering or already taking TYVASO? Please complete the form below to connect with us for helpful updates, information, and support.

*Required field

Privacy

By clicking the SUBMIT button, I understand that I am giving United Therapeutics Corporation and its affiliates and business partners permission to use my personal information to provide me with information related to the TYVASO Support Program, as well as treatment options and services provided by United Therapeutics. I understand that United Therapeutics and its contractors will not sell or rent my personal information. I understand I may revoke my permission at any time by clicking the unsubscribe link at the bottom of the page. For more information, please read the Privacy Policy.

If you have been prescribed TYVASO for PH-ILD, you can get support from a United Therapeutics Virtual Patient Educator* through the Archways Program.

*United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your Healthcare Provider with any specific questions or concerns about your treatment.